Contract manufacturer qualified six peptide actives in one coordinated batch for its house range
A contract manufacturer was expanding its stock peptide-serum platform and needed to qualify six actives across several claim categories at once — firming, expression-line, eye-area, and brightening — rather than running six separate sourcing exercises. A single coordinated qualification cycle cleared all six in 12 weeks.
Published May 18, 2026 · Anonymized customer story
Inquiry → six actives qualified
12 weeks (single cycle)
Actives qualified at once
6 · across 4 claim categories
Forecast / documentation structure
1 (shared across clients)
Claim categories added
Firming · expression-line · eye-area · brightening
Challenge
The manufacturer ran a catalogue of stock cosmetic bases its brand-owner clients customised, and demand had outgrown the two peptides on its approved-actives list. The Director of Formulation wanted to qualify six actives in one coordinated cycle — a Matrixyl-family matrikine and Tripeptide-10 Citrulline (firming), SYN-AKE (expression-line), Eyeseryl and Dipeptide-2 (eye-area), and Nonapeptide-1 (brightening) — each against the relevant house base, with documentation structured so any brand-owner client could pull a per-active packet for their own destination-market notification. Six separate sourcing-and-qualification exercises would have consumed a quarter; the goal was a single supplier, a single forecast, and one documentation structure.
Approach
Pepoderma quoted all six actives against a single 12-month forecast, with lot-level INCI documentation structured so per-client packets could be generated from each underlying lot release. The qualification was scoped by mechanism so the manufacturer's QC could batch the work: the lipidated firming matrikine and SYN-AKE/Tripeptide-10 Citrulline/Eyeseryl/Dipeptide-2/Nonapeptide-1 each mapped to a handling profile (co-solvent pre-disperse for the lipidated active, cool-and-late water-phase add for the water-soluble ones), and each was validated against the house base its claim category targeted. Every lot carried INCI name, CAS where applicable, and an allergen and trace-impurity sheet; the eye-area actives shipped with a note that eye-contour tolerance testing remained the finishing brand's responsibility, and Acetyl Hexapeptide-30's identity was documented by INCI plus COA rather than a guessed CAS.
Outcome
All six actives cleared the manufacturer's qualification inside a single 12-week cycle, drawing on one forecast and one documentation structure. The manufacturer added all six to its approved-actives list and could offer brand-owner clients stock bases across firming, expression-line, eye-area, and brightening claim categories without re-qualifying per client. The per-active packet structure meant the first three clients to build on the new bases each pulled their own destination-market documentation without the manufacturer's team rewriting the same data, and subsequent reorders ran against the standing forecast.
“Six actives, four claim categories, one qualification cycle. Batching the work by mechanism and getting one documentation structure I could hand to any client — that is what turned a quarter of sourcing into twelve weeks, and it is why my approved-actives list finally matches what my clients are asking for.”